Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Boston Scientific Corporation is set to cut approximately 36 jobs as part of a manufacturing shift out of Massachusetts. The company is relocating its manufacturing operations, which has led to the decision to reduce its workforce in the area. This move reflects broader trends in the life sciences sector, where companies are adjusting their operational strategies. The layoffs are part of a restructuring effort aimed at optimizing production capabilities and responding to market demands. The specific timeline for the job cuts has not been detailed in the article.
Boston Scientific Corporation has announced plans to cut jobs following the discontinuation of a heart device. The decision comes as part of a broader strategy to streamline operations and focus on core products. While specific numbers of affected employees and locations have not been disclosed, the company is expected to implement these job cuts in the near future. The layoffs reflect ongoing challenges in the medical device market and the need for Boston Scientific to adapt to changing demands.
No one has shared a story from Boston Scientific Corporation yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.